Open AccessZinc-α2-glycoprotein 1 attenuates non-alcoholic fatty liver disease by negatively regulating tumour necrosis factor-α
Author(s) -
Ting Liu,
Xin Luo,
Zhenghong Li,
Jun-Cheng Wu,
Shengzheng Luo,
Ming-Yi Xu
Publication year - 2019
Publication title -
world journal of gastroenterology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v25.i36.5451
Subject(s) - fatty liver , medicine , endocrinology , lipogenesis , fatty acid synthase , steatosis , cancer research , biology , chemistry , lipid metabolism , disease
Zinc-α2-glycoprotein 1 (AZGP1) plays important roles in metabolism-related diseases. The underlying molecular mechanisms and therapeutic effects of AZGP1 remain unknown in non-alcoholic fatty liver disease (NAFLD).